Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iFCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
NCT02251548Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2014
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Dana-Farber Cancer Institute. Started Oct 2014; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02251548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02251548.